Cardinal Health (NYSE:CAH) Price Target Raised to $277.00 at Wells Fargo & Company

Cardinal Health (NYSE:CAH) had its target price lifted by equities research analysts at Wells Fargo & Company from $245.00 to $277.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 15.38% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on CAH. Robert W. Baird upped their price target on shares of Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a report on Wednesday. TD Cowen boosted their target price on shares of Cardinal Health from $255.00 to $275.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Morgan Stanley increased their target price on shares of Cardinal Health from $245.00 to $255.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Zacks Research cut shares of Cardinal Health from a “strong-buy” rating to a “hold” rating in a report on Friday, June 12th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Cardinal Health from $243.00 to $215.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Fifteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Cardinal Health currently has a consensus rating of “Moderate Buy” and an average target price of $256.73.

Cardinal Health Stock Performance

CAH opened at $240.08 on Wednesday. The company has a market capitalization of $56.23 billion, a PE ratio of 36.71, a P/E/G ratio of 1.16 and a beta of 0.49. The stock’s fifty day moving average is $228.37 and its 200-day moving average is $216.66. Cardinal Health has a one year low of $137.75 and a one year high of $258.30.

Cardinal Health (NYSE:CAH) last announced its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.49. The business had revenue of $63.67 billion during the quarter, compared to analysts’ expectations of $65.15 billion. Cardinal Health had a negative return on equity of 92.61% and a net margin of 0.62%.The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $2.08 earnings per share. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities research analysts forecast that Cardinal Health will post 10.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CAH. Westpac Banking Corp purchased a new stake in Cardinal Health in the 2nd quarter worth approximately $6,980,000. Korea Investment CORP acquired a new stake in shares of Cardinal Health during the 2nd quarter valued at $34,623,000. EP Wealth Advisors LLC purchased a new position in shares of Cardinal Health during the 2nd quarter valued at $1,602,000. Rakuten Securities Inc. purchased a new position in shares of Cardinal Health during the 2nd quarter valued at $71,000. Finally, Callan Family Office LLC acquired a new position in shares of Cardinal Health in the second quarter worth $2,700,000. Institutional investors and hedge funds own 87.17% of the company’s stock.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Profit and guidance beat expectations. Cardinal Health reported fiscal Q4 non-GAAP EPS of $2.91, up from $2.08 a year earlier and $0.49 above consensus. Fiscal 2027 adjusted EPS guidance of $12.40–$12.60 also exceeded the approximately $12.05 analyst estimate, implying 13%–15% growth. Cardinal Health forecasts full-year profit above estimates on specialty drug strength
• Positive Sentiment: Specialty-drug and medtech performance supported earnings. Sustained demand for specialty pharmaceuticals helped drive the outlook, while medical technology profits nearly doubled in the quarter. Cardinal also said it now exclusively serves nearly half of the cell-and-gene therapy market, strengthening its position in a higher-margin growth niche. Cardinal Health nearly doubles medtech profits, fueling Q4 earnings beat
• Positive Sentiment: Large buyback authorization added support. The board approved an additional $5 billion for share repurchases after Cardinal bought back $1.4 billion of stock during fiscal 2026. The company also declared a quarterly dividend of $0.5158 per share, payable October 15. Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results
• Neutral Sentiment: Revenue growth was solid but missed forecasts. Fourth-quarter revenue rose 6% year over year to $63.67 billion, but fell short of the roughly $65.15 billion consensus estimate. Fiscal 2026 operating cash flow reached $5.2 billion and adjusted free cash flow was $5.0 billion. Cardinal Health shares rise as profit beats estimates and outlook tops forecasts
• Negative Sentiment: Some earnings quality and valuation concerns remain. About $0.31 of quarterly adjusted EPS came from a one-time IEEPA tariff refund, while the Global Medical Products and Distribution segment reported declining revenue. With CAH trading near its 52-week high and at an elevated valuation, investors may demand continued execution to justify further gains. Can Cardinal Health’s Strong Earnings Guidance Offset a Mixed Quarter?

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.